MG
GSK icon

Mather Group’s GSK GSK Stock Holding History

Mather Group’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132K Buy
2,515
+1,241
+97% +$65.6K ﹤0.01% 870
2026
Q1 		$70.3K Buy
+1,274
New +$69K ﹤0.01% 977
2025
Q4 		– Sell
-755
Closed -$32.6K – 1053
2025
Q3 		$32.6K Buy
+755
New +$29.5K ﹤0.01% 1007
2025
Q2 		– Sell
-425
Closed -$16.5K – 1062
2025
Q1 		$16.5K Buy
425
+133
+46% +$4.87K ﹤0.01% 1134
2024
Q4 		$9.88K Sell
292
-436
-60% -$15.7K ﹤0.01% 1251
2024
Q3 		$29.7K Buy
728
+185
+34% +$7.57K ﹤0.01% 978
2024
Q2 		$23.3K Buy
543
+305
+128% +$12.8K ﹤0.01% 1233
2024
Q1 		$8.82K Buy
+238
New +$9.81K ﹤0.01% 1231

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mather Group's GSK Position: Q2 2026 in Review

Mather Group increased its GSK (GSK) stake by 97% in Q2 2026, buying an estimated $65.6K and bringing the position to 2,515 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #870.

Mather Group first reported a position in GSK in Q1 2024 and has held it in 8 quarters since. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Mather Group held 2,515 shares of GSK worth $132K as of Q2 2026.
  • Mather Group bought 1,241 GSK shares in Q2 2026, an estimated $65.6K.
  • GSK made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #870 holding.
  • Mather Group first reported a position in GSK in Q1 2024 and has held it in 8 quarters since.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.